- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Novartis Says CGRP Migraine Blocker Shows Good Results in Late-Stage Study
Novartis' calcitonin gene-related peptide (CGRP) inhibitor for prevention of migraine, erenumab, showed positive results in a phase 3b study in episodic migraine patients who have failed multiple prior preventive treatments.
Novartis' calcitonin gene-related peptide (CGRP) inhibitor for prevention of migraine, erenumab, showed positive results in a phase 3b study in episodic migraine patients who have failed multiple prior preventive treatments.
Erenumab (AMG 334) achieved at least a 50% reduction of migraine days versus placebo, and all secondary endpoints, including:
- reduction of monthly migraine days
- reduction in days needing rescue medication
- improvement in scores on the Migraine Physical Function Impact Diary (MPFID) tool
- and 75% and 100% responder rates (number of patients experiencing at least a 75% or 100% reduction in monthly migraine days compared to placebo)
The monoclonal antibody is currently under FDA review. If approved, it will be administered once-monthly using a self-injection device.
Novartis and Amgen will co-commercialize erenumab in the US. Amgen has exclusive commercialization rights to the drug in Japan and Novartis has exclusive rights to commercialize in the rest of the world.
The Institute for Clinical and Economic Review (ICER) is reviewing erenumab and other CGRPs for clinical effectiveness and value. The analysis is expected later this year.
A coverage with evidence development (CED) study demonstrated significant and clinically meaningful benefits in patients with migraine treated with remote electrical neuromodulation (REN). Health plans should support clinicians’ REN prescriptions by ensuring adequate coverage.
Read More
Update on Migraine Patient Care Challenges During the Pandemic
October 5th 2021Migraines plague some 35 million Americans, the majority of them women in their 30s and 40s, and disabling pain and symptoms are linked to lost productivity at work, school, and home. On this episode of Managed Care Cast, we bring you an excerpt of an interview with a headache specialist about the extra challenges for patients and providers during the pandemic.
Listen
Incorporating Discussions of Cannabis Use Into Oncology Care Visits
September 15th 2024The legalization of recreational marijuana in Minnesota has created daily conversations about how to incorporate the use of cannabis into treatment plans for patients with cancer, explained Marie Parish, PharmD, BCOP, of Mayo Clinic.
Read More
How Can Digital Care Programs Aid Those With Chronic Musculoskeletal Pain?
June 9th 2020On this episode of Managed Care Cast, we speak with Jeffrey Krauss, MD, chief medical officer of Hinge Health and Stanford Clinical assistant professor, about the efficacy of a 12-week digital care program aimed to reduce lower back and knee pain in a real-world population.
Listen
Prior Authorization Requirements for Calcitonin Gene-Related Peptide Antagonists
April 20th 2023This quantitative and qualitative analysis highlights differences in prior authorization requirements for migraine drugs from nearly 50 managed care organizations and summarizes broad types of criteria used.
Read More
